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Introduction
Small interfering RNAs (siRNAs) have recently demonstrated 
their potential as novel therapeutics due to their ability to 
induce robust, sequence-specific gene silencing in cells.1,2 
However, several challenges, particularly related to delivery, 
surrounding the use of siRNA in vivo still need to be optimized 
before the full potential of therapeutic RNA interference is 
realized. Due to the polyanionic nature of the molecule, the 
cellular uptake of naked siRNA on its own is extremely low. 
These molecules are also highly susceptible to degradation 
by enzymes both in tissue and intracellularly as well as sys-
temically in the blood. Therefore, to become an effective clini-
cal tool, an efficient, targeted, and tolerable in vivo delivery 
method must be identified. Using siRNA to induce RNA inter-
ference could become a promising therapeutic for treatment 
of many disorders, such as some cancers and many viral 
and genetic diseases. Although some trials involving siRNA 
have entered the clinic, delivery of siRNA, particularly locally 
for dermal applications, remains a key challenge. Indeed, the 
potential for clinical success of siRNA therapeutics hinges on 
an efficient and targetable delivery system.
In addition to improvements in the stability of the molecule 
which can be achieved through chemical modification, multiple 
delivery  strategies  for  siRNA  have  also  been  attempted. 
These include both physical and carrier-mediated methods. 
Examples of drug delivery through carrier-mediated methods 
include the traditional liposomal methods such as lipid nano-
particles,3 as well as ultrasound and microbubble delivery.4
Electroporation  (EP)  represents  a  physical  method  to 
temporarily increase the permeability of a target tissue to 
macromolecules. EP involves the application of brief electri-
cal pulses that result in the creation of aqueous pathways 
within the lipid bilayer membranes of mammalian cells. This 
transient perturbation of the lipid bilayer allows the passage 
of large molecules, including nucleic acids, across the cell 
membrane which otherwise is less permeable. As such, EP 
increases the uptake of macromolecules delivered to their 
target tissue. EP has now entered the clinic as an enabling 
technology  for  the  delivery  of  DNA  vaccines  and  immune 
therapies. The technology has proven to be a safe and effec-
tive DNA delivery method in multiple trials delivering an array 
of genetic vaccines.5–7
We  have  previously  reported  on  a  subcutaneous  DNA 
EP delivery device with a penetration depth of 3 mm (CEL-
LECTRA-3P)8 as well as three intramuscular DNA delivery 
devices, the Medpulser,9 ELGEN,5 and CELLECTRA-5P10–12 
devices  (Inovio  Pharmaceuticals,  San  Diego,  CA).  These 
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Electroporation (EP) of mammalian tissue is a technique that has been used successfully in the clinic for the delivery of genetic-
based vaccines in the form of DNA plasmids. There is great interest in platforms which efficiently deliver RNA molecules such 
as messenger RNA and small interfering RNA (siRNA) to mammalian tissue. However, the in vivo delivery of RNA enhanced by 
EP has not been extensively characterized. This paper details the optimization of electrical parameters for a novel low-voltage 
EP method to deliver oligonucleotides (both DNA and RNA) to dermal tissue in vivo. Initially, the electrical parameters were 
optimized for dermal delivery of plasmid DNA encoding green fluorescent protein (GFP) using this novel surface dermal EP 
device. While all investigated parameters resulted in visible transfection, voltage parameters in the 10 V range elicited the most 
robust signal. The parameters optimized for DNA, were then assessed for translation of successful electrotransfer of siRNA into 
dermal tissue. Robust tagged-siRNA transfection in skin was detected. We then assessed whether these parameters translated 
to successful transfer of siRNA resulting in gene knockdown in vivo. Using a reporter gene construct encoding GFP and tagged 
siRNA targeting the GFP message, we show simultaneous transfection of the siRNA to the skin via EP and the concomitant 
knockdown of the reporter gene signal. The siRNA delivery was accomplished with no evidence of injection site inflammation 
or local tissue damage. The minimally invasive low-voltage EP method is thus capable of efficiently delivering both DNA and 
RNA molecules to dermal tissue in a tolerable manner.
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devices cover injection depths between 3 and 25 mm, typi-
cally suited for subcutaneous and/or intramuscular vaccine 
delivery  using  distinct  EP  array  configurations.  Extensive 
studies have highlighted the critical requirement for optimi-
zation of both the EP device and the parameters used for 
successful delivery which additionally are dependent on both 
the target tissue and the DNA construct to be delivered.8 
Combining  optimized  EP  delivery  methods  with  optimized 
constructs has led to the successful translation of DNA vac-
cination into a clinical setting.5,13–15
While the body of evidence for both preclinical and clinical 
success of enhanced DNA delivery by EP is strong, the char-
acterization of EP-enhanced RNA delivery is not as clear. 
However, electrically assisted delivery of siRNA has been 
documented in a variety of tissues including the cornea,16 
solid tumors,17–19 joints,20 muscle,21 brain tissue,22 and skin.23 
Certainly DNA and RNA differ both physically and electro-
chemically. These differences affect the dielectric properties 
of the molecules and as such could impact their ability to be 
successfully transfected in vivo using EP. The basis for EP is 
the application of an external electrical field which results in 
a significant increase in the permeability of the cell plasma 
membrane. Therefore the size, structure, and charge of the 
molecule to be transfected could significantly affect the ability 
of that molecule to permeate and/or interact with the mem-
brane. Plasmid DNA, generally ranging in size from 3–5 kb, 
exists  in  solution  primarily  in  supercoiled  form  (75–80%). 
Supercoiled or covalently closed-circular DNA is a relatively 
large (3–5 kb; 2–4 Mda) contorted and double-stranded mol-
ecule adopting a highly compacted structure.24 The structure 
of siRNA on the other hand is a short (usually 21-nts) double-
stranded RNA with 2-nt 3′ overhangs on either end. Clearly, 
the optimal transfer dynamics of these two nucleotide mol-
ecules could be widely disparate.
Here we investigated the delivery of siRNA to skin and 
optimized the EP conditions for delivery using a surface EP 
(SEP) device with a novel 4 × 4 minimally invasive needle 
array.25 This SEP device differs from other EP devices in that 
the electrodes are minimally invasive (scratch the skin sur-
face but do not penetrate the skin).
Initially,  the  electrical  parameters  were  optimized  using 
plasmid  DNA  encoding  green  fluorescent  protein  (GFP). 
These  parameters  were  then  assessed  for  translation  to 
electrotransfer of siRNA using a fluorescently tagged siRNA 
for  detection. We  then  investigated  the  delivery  of  tagged 
siRNA to skin through histological methods and additionally 
assessed the ability of EP to enhance targeted gene knock-
down in dermal tissue.
In summary, this study sought to answer two fundamental 
questions: first, can EP be used to efficiently deliver siRNA 
in vivo in a functionally relevant manner and second, whether 
parameters optimized for DNA transfection may also be used 
for RNA delivery, especially at the low-voltage settings?
Results
A  range  of  voltage  parameters  results  in  successful 
expression of GFP in dermal tissue. We have previously 
reported on the development of the 4 × 4 SEP25 where we 
optimized critical parameters such as electrical pulse pattern, 
needle array geometry and electrode configuration, depth of 
penetration, and operating conditions under constant current 
or constant voltage configurations. With the early develop-
ment accomplished, we sought to further explore effective 
voltage parameters for the SEP device, and to this end con-
ducted reporter gene (plasmid-expressing GFP) expression 
and localization studies in guinea pig skin following EP with 
the SEP device. Separate skin sites on the flank of a hairless 
guinea pig were injected with 50 µl of GFP plasmid (@ 1 mg/ml 
concentration) and immediately pulsed (single 100 ms pulse) 
using the SEP set at a series of voltage parameters rang-
ing between 10–200 V (Figure 1a). Robust GFP transfection 
was seen using the 10- and 50-V parameters, with the 10-V 
treatment  appearing  stronger  and  more  reproducible  than 
the 50-V treatment. The skin area transfected following the 
Figure 1  A range of voltage parameters results in delivery of DNA plasmid expressing GFP to guinea pig skin using the SEP 
device. Guinea pig skin was injected intradermally with 100 µg of DNA plasmid expressing GFP (pgWIZ-GFP) and either left untreated or 
immediately pulsed with the SEP device at a voltage setting of 200, 100, 50 or 10 V for one pulse. Skin biopsies were harvested 48 hours 
later and observed by fluorescent microscopy (a) for determination of GFP positive signal or bright light (b) for determination of local treat-
ment site reaction. Bar is included for approximation of site reaction size. GFP, green fluorescent protein; SEP, surface electroporation.
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10-V treatment corresponded in size (~4 mm2) to the surface 
area of the SEP device and the injection bubble size (4 mm 
diameter). Although GFP transfection was detected following 
the 100- and 200-V parameters, unexpectedly, the signal was 
significantly weaker than the 10- and 50-V treatments and 
appeared far less reproducible over multiple treatment sites. 
GFP transfection was visible 8 hours following treatment and 
peaked at 3 days. In contrast, minimal or no GFP transfection 
was detectible following GFP plasmid injection alone.
Direct  contact  between  the  skin  and  electrical  devices 
could result in tissue damage. To assess the effect of   voltage 
parameters  on  dermal  integrity,  the  guinea  pig  skin  was 
assessed  for  signs  of  tissue  damage,  including  redness, 
swelling and/or burning following the treatments detailed in 
Figure 1a across several voltage settings (Figure 1b). At 48 
hours post-treatment, skin sites pulsed with 200, 100, and 50 
V all showed signs of redness and swelling which reduced 
in severity with a reduction in voltage. Not surprisingly, the 
200 and 100 voltage treatments showed significant surface 
burning of the skin resulting in scabbing and inflammation. 
Only the no EP, injection only control group and the 10 V 
treatments showed no visible signs of tissue damage. Thus 
the lower voltage parameters resulted in not only a more effi-
cient delivery of DNA, but also led to a more tolerable EP 
procedure.
Lower  voltage  parameters  result  in  higher  antibody 
titers  to  NP  protein.  Although  establishing  the  expres-
sion patterns for a plasmid reporter gene allowed us to 
gain insight into parameter optimization, a key determinant 
for assessing efficient EP is induction of immunogenicity. 
As such, we then sought to establish the optimal param-
eters leading to a functional immune response. Since sig-
nificant tissue damage resulted from pulsing the SEP at 
200 and 100 V for intradermal delivery, the immune study 
was conducted with the 50- and 10-V parameters. Hart-
ley guinea pigs were immunized with plasmid DNA encod-
ing for NP influenza antigens. Matched NP antigen from 
Puerto  Rico/39  strain  was  optimized,  synthesized,  and 
then cloned into the backbone of a mammalian expression 
vector, pMB76.5, which has been used in previous human 
clinical trials. Animals were immunized intradermally with 
100 µg of DNA at week 0 and were boosted at week 3 
with the same amount of DNA at week 3. Groups of guinea 
pigs  (four/group  EP  or  three/group  injection  only)  were 
electroporated either with the SEP device at the 50 or 10 
V setting or left as injection only without EP. As seen in 
Figure 2, at week 7, robust   antibody titers were generated 
by both EP conditions, although the titers in the 10-V treat-
ment group were double (~60, 000) compared to those in 
the 50-V group (~30, 000). The titers in the injection only 
group were approximately tenfold less than the EP groups. 
Interestingly, the reproducibility of the titers generated was 
consistently better for the 10-V group over the 50-V group 
as determined by the scatter of the plotted titers.
A  range  of  voltage  parameters  results  in  successful 
delivery of tagged siRNA to dermal tissue. In a bid to 
establish effective voltage parameters for siRNA delivery by 
the SEP device, we carried out a localization study using a 
fluorescently tagged siRNA in guinea pig skin following SEP 
at  defined  parameters.  First  we  investigated  whether  the 
parameters that resulted in effective plasmid delivery were 
similar  for  optimal  siRNA  delivery.  Separate  skin  sites  on 
the flank of Hartley guinea pigs were injected with 50 µl of 
siRNA-tagged with Alexa-488 (@ 2 mg/ml concentration) and 
immediately pulsed (single 100 ms pulse) using the SEP set 
at a series of voltage parameters ranging between 10–200 V 
(Figure 3). Two days post-treatment, the animals were eutha-
nized and 8 mm skin biopsies were removed and visualized 
under  a  fluorescent  microscope.  Strong  Alexa  signal  was 
detected using all voltage parameters, with the 10-V treat-
ment appearing to elicit the strongest signal. Minimal or no 
Alexa signal was detectible following injection of the tagged 
siRNA with no EP.
Dermal EP results in robust siRNA-Cy3 signal present 
48  hours  post-treatment.  We  next  continued  the  inves-
tigation of siRNA delivery enhanced by EP using the 10-V 
parameters, since this parameter set appeared to have both 
the optimal delivery efficiency and the least-associated tis-
sue damage. Skin biopsies were taken and histological anal-
ysis was carried out to assess delivery efficiency of EP for 
siRNA at the cellular level. Separate skin sites on the flank of 
Hartley guinea pigs were injected with 50 µl of siRNA-tagged 
with Cy3 (@ 2 mg/ml concentration) and either immediately 
pulsed (three 100 ms pulses) using the SEP set at 10 V or 
left as injection only controls (Figure 4). Two days post-treat-
ment, the animals were euthanized and 8 mm skin biopsies 
were removed, fixed, and prepared for paraffin sectioning. 
Sections  were  stained  with  4′,6-diamidino-2-phenylindole 
(DAPI) and visualized under a microscope for positive Cy3 
signal. At 48 hours, little or no Cy3 signal was detected in 
the injection only controls. However, robust Cy3 signal was 
detected in the EP group.
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Figure 2  Lower voltage parameters result in higher antibody 
titers to NP protein in guinea pigs. Guinea pig skin was inject-
ed intradermally with 100 µg of DNA plasmid-expressing NP and 
  either left untreated (ID only) or immediately pulsed with the SEP 
device at a voltage setting of 50 or 10 V. Animals were immunized 
at day 0 and day 21. Blood was harvested weekly and analyzed 
for the presence of binding antibodies against NP by ELISA. Data 
shown here is from day 49. ELISA, enzyme-linked immunosorbent 
assay; ID, intradermal; SEP, surface electroporation.Molecular Therapy–Nucleic Acids
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Surface EP results in siRNA-Cy3 signal with confirmation 
by siRNA-specific FISH, and GFP expression colocalized 
to the stratum corneum and epithelial cells. We further 
assessed the localization of the signal to specific layers of the 
skin using histological techniques (Figure 5). Separate skin 
sites on the flank of Hartley guinea pigs were injected with 
50 µl of siRNA-tagged with Cy3 (@ 2 mg/ml concentration) 
and immediately pulsed (three 100 ms pulses) using the SEP 
set at 10 V (Figure 5a). Two days post-treatment, the ani-
mals were euthanized and 8 mm skin biopsies were removed 
and  fixed  and  prepared  for  paraffin  sectioning.  Sections 
were stained with DAPI and visualized under a high power 
microscope for positive Cy3 signal. The majority of the signal 
was localized to the upper layers of the epidermis (stratum 
corneum). However, Cy3 signal was also detected in epider-
mal cells throughout the stratified layers, from the basement 
membrane to the surface. No Cy3 signal was detected in the 
dermis, which is in keeping with the mode of action of this 
delivery device.
Furthermore,  siRNA  localization  as  detected  by  Cy3 
signal was confirmed by fluorescent in situ hybridization 
(FISH)  using  probes  specific  to  the  antisense  strand  of 
the siRNA (Figure 5b). Serial skin sections to those ana-
lyzed for Cy3 signal were hybridized to a 5′DIG-labeled, 
locked nucleic acid (LNA) enhanced anti-antisense siRNA 
probe  and  treated  with  a  fluorescein  tyramide  signal 
amplifier.  Sections  were  visualized  for  both  positive  Cy3 
and   fluorescein signal. As shown in Figure 5c, there was 
significant accumulation and clear colocalization of the sig-
nals to the stratum corneum. In additon, fluorescein signal 
was detected to a lesser extent in the epidermal layers, as 
was seen with Cy3 signal.
To address whether plasmid DNA and siRNA can colo-
calize  when  codelivered,  plasmid  DNA  expressing  GFP 
(100 µg) was mixed with siRNA-tagged with Cy3 (100 µg) 
and simultaneously injected into the skin of guinea pigs fol-
lowed by EP using the 10-V settings. The biopsies were 
prepared as described above but this time visualized for 
both positive Cy3 signal and positive GFP signal. There 
was  clear  colocalization  of  both  signals  to  the  stratum 
  corneum. Both signals were also detected in cells in the 
epidermis.  Although  highly  likely,  we  were  nevertheless 
unable to definitively determine visually whether any single 
cell contained both signals.
Dermal  EP  results  in  targeted  reporter  gene  knock-
down in dermal tissue. Having demonstrated successful 
delivery of tagged siRNA to skin through histological meth-
ods, we wanted to assess whether EP-enhanced siRNA 
delivery would result in targeted gene knockdown in dermal 
tissue. Separate skin sites on the flank of Hartley guinea 
pigs were injected with 20 µg siRNA-GFP mixed with 25 µg 
plasmid-expressing GFP immediately pulsed (three 100 ms 
pulses) using the SEP device set at 10 V (Figure 6a). The 
expression of GFP in this group was compared to the plas-
mid only group. Negative controls of plasmid injection only 
and plasmid injection plus non-matched (luciferase) siRNA 
were also included. Representative examples of biopsies 
are shown here. Twenty-four hours post-treatment, the ani-
mal was euthanized and 8 mm skin biopsies were removed. 
The biopsies (four for each siRNA group and eight from 
the plasmid only groups) were visualized under fluorescent 
microscopy and pixel counting software used to quantify 
the signal (Figure 6b). Visually, there was a clear reduc-
tion in the GFP signal in the group where siRNA-GFP was 
codelivered with the plasmid. The plasmid only and plasmid 
plus  siRNA-Luc  (non-matched  control)  appeared  similar. 
The pixel density quantification (determined from the aver-
age  of  multiple  samples)  demonstrated  an  approximate 
50% reduction in GFP signal. As is consistent with previ-
ous experiments, little or no GFP signal was detected in the 
plasmid injection alone group.
No EP 200 v 100 v 50 v 10 v
Figure 3  A range of voltage parameters results in successful delivery of tagged siRNA to guinea pig skin using the SEP device. 
Guinea pig skin was injected intradermally with 100 µg of siRNA-tagged with Alexa 488 and either left untreated or immediately pulsed with 
the SEP device at a voltage setting of 200, 100, 50 or 10 V for three pulses. Skin biopsies were harvested 48 hours later and observed by 
fluorescent microscopy for determination of positive signal. Bar is included for approximation of biopsy size. SEP, surface electroporation; 
siRNA, small interfering RNA.
Figure 4  Dermal electroporation results in robust siRNA-Cy3 
signal present 48 hours post-treatment. Guinea pig skin was 
injected intradermally with 100 µg of siRNA-tagged with Cy3 and 
either left untreated or immediately pulsed with the SEP device at 
10 V for three pulses. Skin biopsies were harvested 48 hours later, 
fixed in formalin, sectioned, and DAPI stained. Slide sections were 
observed by fluorescent microscopy for determination of positive 
signal.  DAPI,  4′,6-diamidino-2-phenylindole;  SEP,  surface  elec-
troporation; siRNA, small interfering RNA.
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Discussion
Due  to  their  ability  to  induce  robust,  sequence-specific 
gene silencing in cells, siRNAs1,2 are an exciting and novel 
therapeutic  option  for  disease  targets  such  as  macular 
degeneration,26  solid  tumors,27  and  melanoma’s.  Indeed, 
clinical programs assessing the safety, tolerability, and phar-
macokinetics of targeted siRNA have now been assessed in 
patients.26,27 However, RNA-based drugs in the absence of 
an appropriate delivery vehicle or method are hampered in 
their applicability due to their low cellular uptake and suscep-
tibility to degradation. As such, to become an effective clinical 
tool, it is important to identify a targeted delivery system that 
can achieve effective transfection of siRNAs.
Our group at Inovio has focused on the design and devel-
opment of novel, innovative solutions to key oligonucleotide 
delivery problems.23,28,29 Since a need exists for more effec-
tive delivery platforms for localized in vivo siRNA delivery, we 
assessed whether our EP platform was a viable solution for 
local siRNA delivery.
The primary interest for this study was to establish whether 
EP  parameters  optimized  to  deliver  plasmid  DNA  would 
translate to effective delivery of RNA in vivo. If successful, 
the ability to deliver distinct nucleic acids would give the EP 
platform far-reaching therapeutic potential. New EP devices 
and parameters optimized for efficacy, tolerability, and safety 
could expand treatment and drug delivery options, especially 
in the field of RNA therapeutics. Both preclinical and clinical 
studies have demonstrated that EP, as an effective physical 
delivery method, can improve both the expression and immu-
nogenicity of DNA vaccines by 100–1,000 fold.
Having previously developed a novel EP device that effec-
tively  targets  dermal  tissue,  we  were  also  keen  to  estab-
lish  optimal  EP  parameters  for  oligonucleotide  transfer 
which could offer both efficient delivery and reduced tissue 
damage.
Initially, using GFP expression as a readout for intracellular 
delivery, we determined parameter ranges for plasmid DNA 
transfection using this EP device, and were able to observe 
transfection of epidermal tissue over a spectrum of voltage 
parameters, ranging from 200 V down to 10 V (Figure 1a). 
Interestingly, GFP transfection at the lowest voltage parameter 
(10 V) appeared more reproducible and robust in comparison 
to the 50–200 V parameters. Although 10 V is considered a 
low-voltage parameter, the actual field strength (a function of 
the electrode distance) is still 67 V/cm, well within the accept-
able range for in vivo EP.30,31 At the higher voltage settings, 
this field strength increases substantially (200 applied volts 
= 1,334 V/cm), resulting in significant cell death as observed 
through histological analysis. This may explain the reduced 
levels of GFP transfection seen when the applied voltage 
is increased for the SEP device. We note that other earlier 
EP devices operate in the 100–200 voltage range for effec-
tive gene delivery. However, for those devices, there is typi-
cally greater separation between electrodes (0.5 to >1.0 cm) 
thereby  maintaining  reasonable  field  strengths  to  achieve 
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Figure 5  Dermal electroporation results in siRNA-Cy3 signal with confirmation by siRNA-specific FISH, and GFP expression 
colocalized to the stratum corneum and epithelial cells. (a) Guinea pig skin was injected intradermally with 100 µg of siRNA-tagged 
with Cy3 and immediately pulsed with the dermal EP device at 10 V for three pulses. Skin biopsies were harvested 48 hours later, fixed in 
formalin, DAPI stained, and sectioned. Slide sections were observed by fluorescent microscopy for determination of positive signal. (b) The 
localization of siRNA was additionally detected by fluroescein-tagged fluorescent in situ hybridization (FISH) to the antisense strand of the 
Cy3-tagged siRNA in guinea pig skin sections serial to those displayed in part A of this figure. (c) Guinea pig skin was injected intradermally 
with a mix of 100 µg of siRNA-tagged with Cy3 and 100 µg DNA plasmid-expressing GFP and immediately pulsed with the dermal EP 
device at 10 V for three pulses. Skin biopsies were harvested 48 hours later, fixed in formalin, sectioned, and DAPI stained. Slide sections 
were observed by fluorescent microscopy for determination of positive signal. DAPI, 4′,6-diamidino-2-phenylindole; GFP, green fluorescent 
protein; siRNA, small interfering RNA.Molecular Therapy–Nucleic Acids
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efficient  gene  transfer  without  significant  tissue  damage. 
Importantly,  efficient  transfection  was  achieved  at  voltage 
settings as low as 10 V without any observable tissue dam-
age with the SEP device.
As seen in Figure 1, transfection of the reporter gene 
plasmid may be occurring; however, the cells may be unable 
to recover from the EP treatment and thus are unable to 
express the plasmid. In support of this theory is the steady 
increase in tissue damage occurring following EP with the 
higher voltage parameters. Visible redness, inflammation 
and in some cases, scabbing was identified following treat-
ments between 50–200 V with the SEP device (Figure 1b). 
We also note that the presence of hemoglobin quenches 
the GFP signal.32
Although exploring plasmid reporter gene expression across 
a wide range of voltage parameters was informative, of greater 
interest was assessing the voltage parameters which resulted 
in an immune response. It was clear that the 100 and 200 
voltage parameters caused significant tissue damage, and as 
a result, reduced plasmid expression upon treatment with the 
SEP device. As such, we limited our assessment to the 50- 
and 10-V parameters to induce humoral immune responses 
as compared to intradermal injection alone (  Figure 2). Both 
the 50- and 10-V parameters illicited responses of significant 
magnitude  against  the  administered  antigen.  However,  the 
spread of the titers was wider in the 50-V group. Indeed, one 
animal’s response was similar in magnitude to the injection-
only control. The reduction in expression due to increased cell 
damage/death  may  also  explain  the  attenuated  responses 
and titers. While only one time point is shown here (week 7), 
the trend towards achieving higher titers with lower voltage 
parameters  was  demonstrated  at  all  time  points,  through 
study completion (week 12).
Ultimately, our primary question for this study was to estab-
lish whether EP would be able to enhance the delivery of 
siRNA  (Figure  3).  Again,  initial  range-finding  experiments 
were conducted using the original DNA-EP parameter set 
(200–10 V) used in Figure 1. Since siRNAs are considerably 
smaller than plasmids, we were unsure whether EP param-
eters optimized for a large circular DNA molecule (~2 kb) 
would effectively deliver a smaller double-stranded RNA (20–
25 nts in length). Using Alexa-488 tagged siRNA, we were 
able to demonstrate that a large range of voltage parameters 
(200–10 V) successfully delivered the siRNA to dermal tis-
sue. There appeared to be a trend towards higher delivery 
efficiency at the lower voltage settings, thus supporting the 
pattern observed with plasmid delivery. Since the siRNA is 
tagged and therefore does not require expression for visu-
alization, (unlike the plasmid DNA), the effect of the tissue 
damage at higher voltages seemed less pronounced in these 
samples. Since the 10-V parameter appeared to induce the 
most effective delivery of siRNA, we wanted to further inves-
tigate the localization of the delivered siRNA in the dermal 
tissue by histological techniques. Forty-eight hours following 
an injection-only delivery displayed no detectable Cy3 siRNA 
in the skin biopsy. However, robust Cy3 signal was present 
in the epidermis of the skin following EP-enhanced delivery 
(Figure 4). At an increased magnification, it was clear that 
the majority of the Cy3 signal was localized to the stratum 
corneum (Figure 5a) which is the upper-most stratified layer 
in the epidermis. However, clear localization of Cy3 could 
also be seen in epithelial cells in the epidermis, from the 
basement membrane up. As cells in the epidermis differenti-
ate they move from the lowest layer (basement membrane) 
to the surface (stratum corneum). The concentrated signal in 
the stratum corneum could potentially be attributed to cells 
transfected  with  Cy3  siRNA  that  are  moving  through  the 
  natural regenerative cycle. The Cy3 signal remained strong 
at 48 hours although it was unclear whether the tag was still 
attached to the siRNA.
In order to confirm the localization of siRNA as detected 
by Cy3 signal, we employed FISH, visualized by a fluores-
cein-tagged tyramide signal amplifier, to detect the antisense 
strand of the siRNA. Analyzing serial sections from the same 
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Figure 6  Delivery of siRNA by the SEP device results in tar-
geted  gene  knockdown  of  reporter  gene  in  dermal  tissue. 
Guinea  pig  skin  was  injected  intradermally  with  25  µg  of  DNA 
  plasmid-expressing GFP (pgWIZ-GFP) left untreated, 25 µg of DNA 
plasmid-expressing GFP and immediately pulsed with the SEP de-
vice or plasmid mixed with either siRNA-GFP or siRNA-Luc (20 µg) 
and immediately pulsed with the SEP device. (a) Skin biopsies were 
harvested 24 hours later and observed under bright light for de-
termination of treatment site location or fluorescent microscopy for 
determination of GFP positive signal. (b) GFP pixel density was de-
termined using pixel counting software as described (see Materials 
and Methods). GFP, green fluorescent protein; luc, luciferase; SEP, 
surface electroporation; siRNA, small interfering RNA.www.moleculartherapy.org
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dermal tissue that was used for Cy3 detection allowed us 
to determine the extent of signal colocalization. As seen in 
  Figure 5b, there was significant accumulation and clear colo-
calization of the Cy3 and fluorescein signals to the stratum 
corneum. Fluorescein signal was detected in the epidermal 
layers; however, to a lesser extent than the stratum corneum 
similar to the observations with direct detection of Cy3 signal. 
These data confirm that the distribution pattern of Cy3 in the 
skin sections is reflects that of siRNA localization and is not 
simply detection of free fluorophore.
We were keen to understand whether simultaneous code-
livery of fluorescent DNA and RNA molecules would result in 
colocalization of signals. To investigate this, plasmid-express-
ing GFP was mixed with Cy3-labeled siRNA and delivered 
simultaneously to skin using the SEP (Figure 5c). There was 
clear colocalization of both signals to the stratum corneum 
and there was also signal in epithelial cells in the epidermis; 
however, it was difficult to determine whether any single cell 
contained both GFP and Cy3-siRNA signals. It also appeared 
that at the 48-hour time point, more cells were Cy3-positive 
than GFP-positive. This may reflect the kinetics of expression 
or stability of GFP in the cell.
While the tagged siRNA allowed us to establish the fea-
sibility of siRNA delivery and optimize delivery parameters, 
the true application would be to demonstrate targeted gene 
knockdown. Using the plasmid expression of GFP, we dem-
onstrated that matched siRNA simultaneously delivered was 
able to significantly knockdown reporter gene expression in 
the skin (Figure 6). As hypothesized, unmatched (siRNA-
Luc) had no effect on GFP expression. We believe that this 
successful demonstration of siRNA delivery to dermal tis-
sue demonstrates that EP-mediated delivery of siRNA is a 
viable option to enhance gene knockdown in the skin and 
could offer a clinical platform for therapeutic options in the 
future. We considered the use of sequential administration 
of GFP plasmid followed by the administration of siRNA at a 
subsequent time point (a day or two later to better model a 
therapeutic effect). However, skin delivery of DNA and siRNA 
to the animal at the same site presents a significant techni-
cal challenge and cannot be adequately controlled. This is 
because over time the injected liquid (and the plasmid or 
siRNA) dissipates away from the injection site, the surface of 
the skin and the underlying dermal layer slide relative to each 
other, and it is difficult to adequately ensure that the same 
cells that receive the reporter plasmid are also getting the 
siRNA molecules. Towards this end, subsequent studies will 
address the effects of improved EP-mediated siRNA delivery 
in surface tumor models and investigate the impact on tumor 
growth. Using a visible tumor model allows us to accurately 
target siRNA delivery to the tumor target directly.
EP has been previously used in several studies to deliver 
siRNA to target tissues. Like the Inoue et al. study,23 we also 
demonstrate successful delivery of siRNA to skin. A distinct 
difference between the two studies is the animal model used. 
Mouse skin was used in the Inoue study which also presents a 
distinct challenge in that because it is very thin, it is difficult to 
control transfection and gene silencing to the skin; instead it is 
likely that both skin and the underlying muscle are impacted. 
In this study, we investigated siRNA transfer in guinea pig 
skin which represents a more relevant dermatological model 
due to its similarities in thickness and physiology to human 
skin. A major advancement in the siRNA delivery protocol that 
we describe here is related to the device and the optimal EP 
parameters. Here we determined that low-voltage parameters 
(10 applied volts or 67 V/cm), which generate minimal current, 
using our SEP device was optimal at siRNA transfer. Indeed, 
such parameters result in no discernable tissue damage and 
as  previously  reported  for  delivery  of  DNA  molecules,  are 
highly tolerable.25 The specific design of the device also lends 
itself to optimized delivery. Due to the grind of the electrodes, 
no  additional  conductive  gel  need  to  be  applied  and  the 
device makes only contact with the surface of the skin. There-
fore from a patient’s perspective, the benefit of combining the 
SEP device with low-voltage parameters for RNA delivery is 
increased tolerability. Achieving efficacy and target specificity 
are crucial elements of this delivery platform.
We not only established that we could enhance RNA deliv-
ery  to  skin  by  EP  and  demonstrate  reporter  gene  knock-
down, we also established that our low voltage, tolerable SEP 
parameters appeared to induce the most effective delivery. 
The EP platform detailed in this study at present is particu-
larly suited to topical RNA delivery applications.
In summary, these data support the idea that RNA delivery 
can be facilitated by EP, much in the same way that DNA 
delivery is, and as such, this platform could pave the way 
for development of targeted RNA-based therapies for local 
applications.
Materials and methods
SEP minimally invasive device design. Electrode arrays con-
sisting of a 4 × 4 gold-plated trocar needle of 0.0175 inch 
diameter at a 1.5 mm spacing were constructed to be used in 
conjunction either with the ELGEN1000 (Inovio Pharmaceu-
ticals, Blue Bell, PA) pulse generator or a battery powered 
low voltage circuit.
Plasmid preparation. The gWiz GFP plasmid was purchased 
from Aldevron (Fargo, ND). The NP plasmid encodes the full-
length NP derived from Puerto Rico 8 (H1N1) strain of influ-
enza  (accession  number:  ADY00024.1). The  construct  had 
the nuclear targeting signals mutated and was optimized and 
synthesized by GeneArt (Grand Island, NY) then cloned into 
the backbone of a mammalian expression vector, pMB76.5. All 
plasmids were diluted in 1× phosphate-buffered saline before 
injection.
siRNA preparation. The Cy3-tagged (Quasar570) and Alexa-
488-tagged  siRNAs  were  synthesized  by  Alynlam,  Cam-
bridge, MA. RNA oligonucleotides were synthesized using 
commercially  available  5′-O-(4,4′-dimethoxytrityl)-2′-O-t-
butyldimethylsilyl-3′-O-(2-cyanoethyl-N,N-diisopropyl)  phos-
phoramidite monomers of uridine (U), 4-N-acetylcytidine(CAc), 
6-N-benzoyladenosine  (ABz),  and  2-N-isobutyrylguanosine 
(GiBu),  according  to  standard  solid  phase  oligonucleotide 
synthesis protocols. For sequences containing Quasar570, 
Quasar 570 amidite (Biosearch Technologies, Novato, CA) 
was directly coupled during RNA synthesis. After cleavage 
and  deprotection,  RNA  oligonucleotides  were  purified  by 
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and characterized by electrospray mass spectrometry and 
capillary  gel  electrophoresis.  RNA  with  phosphorothio-
ate  backbone  at  a  given  position  was  achieved  by  oxida-
tion  of  phosphite  during  oligonucleotide  synthesis  using 
  0.1 mol/lDDTT (3-(dimethylaminomethylene) amino-3H-1, 2, 
4-  dithiazole-5-thione). For sequences containing Alexa 488, 
the conjugation of the dye was done using the Alexa488 suc-
cinimidyl ester (Invitrogen, Carlsbad, CA) post-synthetically to 
the corresponding purified amino-containing RNA precursor.
The GFP-siRNA and Luc-siRNA was purchased from Bion-
eer, Daejeon, Korea. The sequence of the GFP sense strand 
was  CGAAGGUUAUGUACAGGAA(dTdT)  and  the  sequence  of   
the luciferase sense strand was UUGUUUUGGAGCACGG 
AAA(dTdT).
The  sense  strand  of  the  tagged  siRNA  is 
5′-UCGAAGUACUCAGCGUAAG-3′ and the antisense strand 
is 5′-CUUACGCUGAGUACUUCGA-3′.
Animals. Female Hartley guinea pigs (strain code 051) and 
female IAF hairless guinea pigs (strain code 161) were pur-
chased  from  Charles  River  Laboratories, Wilmington,  MA. 
Guinea pigs (four animals per group for immune study) were 
housed at BioQuant (San Diego, CA).
All  animals  were  housed  and  handled  according  to  the 
standards of the Institutional Animal Care and Use Commit-
tee (IACUC).
Preparation of animals. The GFP reporter results observed 
on the Hartley guinea pigs after hair removal were the same 
as the results observed on the IAF hairless guinea pigs in the 
initial plasmid localization experiments. Since hair removal 
appeared to have no effect on the resulting transfection and 
due to cost considerations, we chose to carry out the immune 
study in Hartley guinea pigs. Hartley guinea pigs were shaved 
and stubble removed by dilapatory cream (Veet) 24 hours 
before treatment.
DNA/siRNA injections. Guinea pigs were injected intrader-
mally (Mantoux method (needle parallel to skin)–29 gauge 
insulin needle) with 50 µl of 1× phosphate-buffered saline 
containing the desired dose of plasmid or siRNA. For the 
immune study, animals were vaccinated twice 3 weeks apart 
with 100 µg plasmid at each immunization.
Dermal device EP. Immediately following injection of DNA 
or siRNA, the dermal device was applied to the site of der-
mal injection. The array was “wiggled” at the injection site to 
ensure good contact and electrotransfer achieved through 
pulse generation either from the Elgen 1000 or a low-voltage 
battery circuit.
Visualization of GFP reporter gene signal. Skin samples or 
biopsies were removed postmortem from animals after termi-
nation and stored on ice until imaged under an OV 100 imag-
ing microscope (AntiCancer, San Diego, CA) at 480 nm.
Pixel  count  method.  The  images  were  processed  using 
Adobe Photoshop CS5. A “gated region” of electrode con-
tact  for  pixel  analysis  was  established  on  the  presump-
tion that transfection occurs only where the electric field is 
applied and that the electric field is formed only where the 
electrodes are in direct contact with the skin. The distance 
between the first and fourth electrode in the SEP device is 
4.5 mm. The “ruler tool” in Photoshop was used to isolate a 
4.5 mm2 region which was defined as ~95 pixels in length. 
The images obtained from the microscopy were 8 bit RGBs 
files. Photoshop is able to recognize pixel intensities rang-
ing from 0–255 (darkest–brightest) in three different chan-
nels (red, green, blue). Intuitively, positive GFP signal would 
predominate in the green channel; therefore, pixel analysis 
was restricted to this channel. The CS5 version of Photo-
shop is able to automatically calculate mean and median 
pixel intensity of a selected region. Since the distribution 
of pixel intensity was not symmetrical in most cases, the 
median gave a better representation of central tendency for 
the histogram.
Histological analysis. Skin samples or biopsies were removed 
postmortem from animals after termination and immediately 
preserved in 10% neutral buffered formalin and processed for 
histopathological analysis. Appropriate tissues were trimmed, 
processed, embedded in paraffin, sectioned at ~5 µm, and 
stained with DAPI. All images were captured on the Zeiss Axio-
vision Microscope (Carl Zeiss, Goettingen, Germany) using 
a ×20 objective.
FISH. Skin sections that were serial to those used for histolog-
ical analysis were processed by FISH using a 5′ DIG-labeled, 
LNA  enhanced  probe  (Exiqon,  Woburn,  MA)  designed  to 
detect the antisense strand of the Cy3-siRNA. The sequence 
of the probe is 5′-AACTTACGCTGAGTACTTC-3′.
Briefly,  deparaffinized  sections  underwent  a  series  of 
blocking steps and were hybridized to the LNA probe over-
night at Tm-20 °C. The hybridization temperature was 50 °C. 
The hybridization buffer is composed of: 5 ml 50% Forma-
mide, 2.5 ml of 20× saline-sodium citrate (SSC), 2 ml of 50% 
  Dextran sulfate, 200 µl of 50× Denhardt’s, and 500 µl of 10 
mg/ml yeast RNA.
Sections  were  washed,  blocked,  and  incubated  with  an 
anti-DIG-HRP antibody (Perkin Elmer, Waltham, MA). A flu-
orescein-fluorophore Tyramide Signal Amplification Kit (Per-
kin Elmer) was used to enhance HRP-generated signal. Skin 
sections were then stained with DAPI and visualized for both 
Cy3 signal (directly tagged to siRNA), and fluorescein signal 
(detection of the AS strand of the Cy3-siRNA). Images were 
overlaid to determine the extent of colocalization.
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